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ABSTRACT 
BACKGROUND: 
 
 Haemophilia, an inherited single gene disorder has an incidence of 1 per 10,000 
births. Although the genetic basis of this disorder has been well studied in India, 
data on the number of patients and trends of the disorder in India have not been 
reported. 
METHODS: 
A cross sectional study including 50 Haemophilia patients was done. After 
obtaining consent from the patients, a detailed clinical history and laboratory 
investigations, including factor assays and ferritin levels were done. Ferritin 
levels were measured by Immunoassay method. 
RESULTS:   
The results showed that severe haemophiliacs formed the major proportion of 
the patients. There were 64% of severe Hemophilia A and 8% were inhibitor 
positive. 42% had a family history of hemophlia. The mean age at diagnosis 
was 6.58 months. Arthropathy involved the weight bearing joints. Ferritin levels 
were found to be in the low normal range with 62.5% of severe Hemophilia A 
patients having a ferritin of less than 50ng/ml. 25% of severe Hemophilia 
patients had a microcytic hypochromic peripheral smear. 4% were positive for 
HBsAg; 2% for HIV and 2% for HCV. 18% had a history of receiving blood 
products for treatment. 
CONCLUSION: 
Most of the patients in the study group were severe haemophiliacs and majority 
of them had a low normal ferritin value with abnormal peripheral smear. The 
weight bearing joints were predominantly involved and the age at diagnosis was 
roughly around the same time as the infants begin to crawl. Blood borne 
infections were still common among the group. Only a very small percentage 
were aware of their mother’s carrier state. 
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     INTRODUCTION 
Haemophilia a group of related bleeding disorders that are inherited. 
Inherited bleeding disorders include abnormalities of coagulation factors and 
platelet function; the most common of which is von Willebrand disease. 
However, when the term "haemophilia" is used, it most often refers to 
Haemophilia A and Haemophilia B. Our country has the second highest burden 
of haemophilia patients in the world. The pathophysiology of Haemophilia A 
and Haemophilia B is based on the insufficient generation of thrombin by the 
factor IXa/factor VIIIa complex through the intrinsic pathway of the coagulation 
cascade1. 
Bleeding may occur anywhere in patients with haemophilia. The most 
common sites are into joints and muscles and from the gastrointestinal tract. 
Approximately 80 percent of haemorrhage occurs in the joints; the ankles are 
most commonly affected in children, and the knees, elbows, and ankles in 
adolescents and adult. Spontaneous hemarthroses are characteristic of severe 
disease. 
Haemophilia has an incidence of about 1 in 10000 in our country. Patients 
present with spontaneous bleeds or post traumatic bleeds depending on the 
severity of the disease. This group of patients are prone to develop chronic 
disability if under treated or untreated. Incidence of premature death is also high 
in this group of patients. 
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Iron deficiency might add on to the morbidity in Haemophiliacs. The iron 
deficiency can be due to the presence of occult blood loss in the urine and stools 
or due to the deposition of iron in the synovial membrane during repeated 
bleeding episodes2. Identifying iron deficiency and treating it in these patients 
might help to improve their quality of living. 
Discovery of the molecular structure of both factor VIII and factor IX has 
recently allowed the development of genetically engineered products, 
prepared using recombinant DNA technology. In the long term, Preparations 
presently prepared form human plasma may be superseded by 
recombinant clotting factor concentrates (a DNA). 
Nearly one third of cases of haemophilia occur with no preceding family 
history, possibly from new genetic mutation. When recorded family 
history is available, efforts should be made to identify female carriers. 
Identification depends on family history, measurement of clotting profile 
and DNA analysis. 
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AIMS AND OBJECTIVES OF THE STUDY 
 
 
 Detailed Clinico haematological evaluation in patients with Haemophilia 
 
 To identify serum ferritin levels in Haemophilia patients and to assess 
iron deficiency. 
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REVIEW OF LITERATURE 
OVERVIEW 
Haemophilia A is an X chromosome-linked hereditary disorder caused by 
defective synthesis or by synthesis of dysfunctional factor VIII molecules. 
Haemophilia A is less common than von Willebrand disease (vWD), but it is 
more common than other inherited clotting factor abnormalities. The clinical 
features of Haemophilia A and Haemophilia B are indistinguishable. Both are 
sex linked disorders. 
They can present as mild moderate or severe forms. In the severe forms of 
both types of haemophilia spontaneous hemarthroses is common and can lead to 
chronic crippling hemarthropathy if not treated early or adequately.  Deficiency 
of these factors leads to ineffective haemostasis due to ineffective thrombin 
formation. Highly purified concentrates and recombinant preparations are 
available for treatment and are considered safe and effective. The major 
complication is the development of antibody inhibitors against Factor VIII or IX 
but it is more common with Factor VIII.   
HISTORY 
The existence of a sex linked bleeding disorder was recognised in the 5th 
century in the Talmund. It was then referred to as “haemorrhaphilia” (love of 
bleeding) in 18281. The disease was recognised when a rabbi identified that sons 
of haemophilia gene carriers were at risk of bleeding following circumcision. In 
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the 19th century several authors recognised the link between bleeding episodes 
to the delayed blood coagulation. Morawitz developed the classical theory of 
coagulation that involved 2 reactions –  
1. Conversion of prothrombin to thrombin by a tissue substance that he named 
as thrombokinase  
 2. Conversion of fibrinogen to fibrin by thrombin3. 
In 1911, Addis contributed to the history of haemophilia by recognising 
that the defect is correctable with a small amount of normal plasma but he 
incorrectly attributed it to the deficiency of prothrombin. With the advent of 
better protein purification techniques in the 1930s and 1940s, the components of 
thrombokinase were identified.  
Brinkhouse was the first to identify that the basic defect was a delayed 
conversion of prothrombin to thrombin.  He corrected it by adding a small 
fraction of plasma containing antihaemophilic factor which was later named as 
factor VIII.  
Until 1952 the presence of Haemophilia B was unnoticed. In 1947 
Pavlovsky found that when he transfused blood from one Haemophilia patient 
into another patient, the clotting abnormality got corrected. But then he wasn’t 
aware that he was dealing with two different types of haemophilia. In 1952, 
Aggeler and his co-workers described a patient deficient in "plasma 
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thromboplastin component," a blood clotting factor different from factor VIII. 
This factor was later named as Factor IX. 
 
    EPIDEMIOLOGY 
International incidence of Haemophilia A is found to be 1 in 5000 to 7000 
live male births. It occurs in all ethnic groups3. 
Severe Haemophilia  -  Factor VIII <1% 
Moderate Haemophilia– Factor VIII 1 to 5 % 
Mild Haemophilia – Factor VIII 6-30% 
50 to 60% of patients have severe haemophilia, 25 to 30% have moderate 
haemophilia and 15 to 20% have mild haemophilia. 
The annual incidence of Haemophilia A has been estimated at 
approximately    1 : 5000 male births . The incidence of Haemophilia B is 
estimated at approximately 1 : 30,000 male birth.3 
The incidence of Haemophilia in India is about 1 in 10000 live male 
births. India is the second largest harbour of haemophilia patients. With the 
present records available number of Haemophilia patients in India is 11586 
while the estimated prevalence is about 500004. 
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Prevalence indicates the number of patients with haemophilia alive at a 
given point of time. Some studies suggest a lower prevalence in the Chinese 
population and a higher prevalence among Caucasians3. 
Prevalence varies with age and the disease is maximum seen in the 
second and third decade of life. 
Haemophilia B occurs 1 in every 25000 to 30000 male births. As with 
Haemophilia A, Haemophilia B also occurs in all ethnic groups and geographic 
distributions.  
 
Figure 1 Hemophilia trends in high burden countries 
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The per capita consumption of factor in India which has the second 
highest number of Haemophilia patient list, is only 0.032 as compared to The 
United States of America which has a factor consumption of 5.17. 
EPIDEMIOLOGY IN INDIA: 
 
Figure 2 Epidemiology 
FUTURE PLANS IN INDIA 
India lacks a proper surveillance system. With the data obtained from 
other developed countries that have an established surveillance system, the 
magnitude of cases in our country can be estimated. India could have around 
70,000 patients as estimated from the prevalence data of USA. This large case 
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load might be due to the improving medical services or due to the increased life 
span of these patients. 
 
With the expected high case load, the need for a national programme for 
Haemophilia must be emphasized. The problem of equity should be kept in 
mind. People from the lower socio economic status and rural areas must be 
made accessible to the factors. Compulsory Hepatitis B vaccination must be 
emphasized. Routine screening for HIV and HCV should be done for persons 
with Haemophilia. 
 
The data on epidemiology and the cost incurred in treating a patient is 
lacking in our country. However, data regarding the genetic basis of the disease 
and the prenatal diagnosis is available. Pre natal diagnosis is carried out in a few 
premier institutes within the country. 
 
Maintaining a Haemophilia registry is important in order to obtain 
information regarding the disease burden and trends in our country.  
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ETIOLOGY 
Haemophilia A is a heterogeneous disorder resulting from the reduced 
levels of functional factor VIII in the peripheral circulation. This can be due to 
either decreased levels of factor VIII or decreased functionality of factor VIII. 
Factor VIII must be activated by thrombin for it to be an effective 
cofactor of factor IXa. Factor IXa’s capacity to activate Factor X is 
exponentially increased in the presence of activated factor VIII - FVIIIa. Thus 
the clinical manifestations of Haemophilia A and B are not very much different 
from each other. Together Factor IXa and VIIIa (X-ase) activate factor X which 
is necessary for effective thrombin formation. In the absence of either factors 
clot formation is delayed and the clot thus formed is easily friable, dislodged 
and subjected to fibrinolysis which leads to excessive bleeding. 
GENETICS 
Haemophilia A and B are X linked recessive disorders. About 30% of 
Haemophilia A mutations can arise de-novo. The gene for Factor VIII is large 
with 26 exons and 25 intervening introns. This makes identification of the 
mutation difficult.  
All the sons of affected haemophiliac males are normal while all the 
daughters are obligatory carriers. Sons of carriers have 50% chance of being 
affected and the daughters of the carriers have a 50% chance of being carriers 
themselves. In female carriers, because of  lyonization there might be 
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preferential expression of the defective haemophilic allele. Such females who 
have Haemophilia are called “lyonized carriers”.  Other mechanisms for female 
Haemophilia include homozygosity for the defective Factor VIII allele and 
hemizygosity for the defective gene. In female haemophiliacs,  karyotyping is 
necessary to rule out   Turner’s syndrome and testicular feminization which has 
been associated with Haemophilia A. No single mutation can cause 
Haemophilia. Hundreds of deletions, point mutations and inversions have been 
identified.  
Analysis of Factor IX mutations show that it occurs due to endogenous 
processes – deamination of CpG dinucleotides rather than from environmental 
effects. As with Haemophilia A, no single gene has been attributed to the 
development of Haemophilia B.  
 
FACTOR VIII gene and HAEMOPHILIA: 
Factor VIII gene contains 186 kb with 26 exons, and produces an mRNA 
transcript of 9kb which is translated into 2351 amino acid polypeptide. The 
mature protein is divided into homologous domains named A1, A2, B, A3, C1, 
C3.The most common defect is inversion of 500-600 kb region that results in 
disruption of F8 region of intron 22. Additoinal inversion of Intron 1 of Factor 
VIII contributes to 5% of severe Haemophilia. Point mutations involving CpG 
dinucleotide are more common. 
  
17 
 
Figure 3 Factor VIII gene 
FACTOR IX GENE AND HEMOPHILIA B: 
The gene for factor IX is located on the long arm of chromosome X. It is 
much smaller than the gene for factor VIII measuring only around 33kb. 
 
Figure 4 Factor IX gene 
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It has been extensively studied when compared to Factor VIII. Eight 
hundred ninety-six distinct mutations in the factor IX gene have been reported 
in the factor IX database, including more than 500 distinct amino acid 
substitutions and 41 complete gene deletions1. Majority of these mutations 
involve the CpG dinucleotide that affects critical arginine molecule, resulting in 
a dysfunctional protein. Haemophilia B Leiden phenotype involves mutation in 
the 5’ promoter region of the gene. This disorder is characterised by very low 
levels and activity of Factor IX at birth, that gradually increases to 60% after 
puberty probably due to the effects of androgen.  
F9 is the gene’s official symbol. The F9 gene is located on the long (q) arm 
of the X chromosome between positions 27.1 and 27.2. More precisely, 
the F9 gene is located from base pair 139,530,732 to base pair 139,565,696 on 
the X chromosome. Other names are Christmas factor, Plasma thromboplastin 
component, HEMB,FA_9HUMAN and a few others. 
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MUTATIONS IN THE PROMOTER EGION OF FACTOR IX 
 
ACTIVATION OF FACTOR IX: 
 
Figure 5 Activation of factor IX 
FACTOR IX GENE: 
 
Figure 6 Factor IX gene 
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GENETICS IN HEMOPHILIA:
 
Figure 7 Pedigree 
 
When a carrier woman marries a normal man, there is a 50% chance of the girl 
children to be carriers and 50% chance of her son to be a Haemophilic. 
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CLOTTING CASCADE :
 
Figure 8 Clotting cascade 
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CLOTTING CASCADE: 
1. VASCULAR CONSTRICTION 
2. PLATELET ACTIVATION 
3. EXTRINSIC PATHWAY 
4. INTRINSIC PATHWAY 
5. FINAL COMMON PATHWAY 
6. COFACTORS 
7. REGULATORS  
8. FIBRINOLYSIS 
 
VASCULAR CONSTRICTION: 
After a trauma, the blood vessel immediately constricts causing reduced 
blood leakage. This occurs due to local myogenic reflex, local autocoid factors 
released by the vessel wall and the platelets and neurogenic reflex. The 
neurogenic reflex originates from the pain nerve endings.  Of the above 
mentioned factors, the myogenic reflex is the most powerful. Of the autocoids, 
the most important vasoconstrictor is the thromboxane A2. The more the injury 
to the vessel, greater is the spasm. The spasm might last from few hours to days 
during which time the coagulation cascade is activated and the process 
continues. 
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PLATELET ACTIVATION: 
If the cut vessel is very small, it can be sealed by the platelet pug itself. 
Many such small leaks keep happening throughout the day. 
 
PLATELET PHYSIOLOGY: 
Platelets or thrombocytes, formed from the megakaryocytes in the bone 
marrow, are small discs measuring about 1 to 4 micrometers in diameter. The 
normal concentration of platelets is around 1,50,000 to 3,00,000 per litre. 
 
The cytoplasm of platelets contain, 
 Contractile proteins like actin, myosin and thrombasthenin 
 Golgi bodies and Endoplasmic reticulum that store large quantities of 
calcium 
 Mitochondria, that synthesise ATP and ADP 
 Enzyme system that synthesizes prostaglandins that act as local hormones 
and play major role in haemostasis. 
 Fibrin stabilizing factor 
 A growth factor that causes vascular endothelial cells, smooth muscle 
cells and fibroblasts to grow. 
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The platelets’ cell membrane has glycoprotein that repulses attachment to the 
vessel wall but gets attached to injured endothelium and exposed collagen. In 
addition platelets contain phospholipids that activate various stages of blood 
coagulation process. The half life of platelets is 8 to 12 days.  
When the platelets come in contact with collagen they change their 
characteristics. They tend to swell up and the contractile process within the 
platelets release the contents of the granules. These make the platelets even 
more sticky and they tend to bind avidly to each other and to the exposed 
collagen and von willebrand factor. It also releases ADP which forms 
Thromboxane A2. This further makes the platelets sticky. A platelet plug is 
formed which is initially loose and then tends to become closely packed. Small 
leaks are closed by platelet plugs themselves. This is the reason why patients 
with thrombocytopenia develop multiple small bleeding spots under their skin 
throughout the day which never happens in a normal individual. 
 
Figure 9 Platelet morphology 
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The coagulation process is initiated by three factors, 
 Damage to bleed vessel 
 Damage to the blood components 
 Exposure of blood to damaged endothelial cells or the underlying collage 
In each instance, it leads to the formation of the prothrombin activator which 
converts prothrombin to thrombin and the coagulation continues. 
 
 
The prothrombin activator can be formed by two processes, 
 EXTRINSIC PATHWAY – Begins with the trauma to the vessel wall 
 INTRINSIC PATHWAY – Begins in the blood itself 
 
EXTRINSIC PATHWAY: 
This is also known as tissue factor pathway.  This begins with the 
exposure of blood to the damaged extra vascular tissue or traumatised vessel 
wall. 
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STEPS: 
1. Release of TISSUE FACTOR:  Damaged vessel releases several tissue 
factors or tissue thromboplastin. They are composed of phospholipids and act 
as proteolytic enzyme. 
 
Figure 10 Extrinsic pathway 
 
2. FACTOR VII AND TISSUE FACTOR: The lipoprotein tissue factor forms 
complexes with Factor VII and in the presence of Calcium catalyzes the 
activation of Factor X to Xa. 
3. Factor Xa combines with Facto V and in the presence of calcium becomes 
the PROTHROMBIN ACTIVATOR. 
4. Prothrombin activator complex in the presence of calcium converts 
prothrombin to thrombin and the coagulation continues.  
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In the prothrombin activator complex, Factor X is the actual protease and Factor 
V accelerates the protease activity. The formed thrombin further activates Factor 
V which becomes an additional accelerator of prothrombin activator thereby 
becoming a positive feedback mechanism. 
INTRINSIC PATHWAY: 
The second pathway for initiating coagulation is the intrinsic pathway 
which gets activate with damage to the blood components. 
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1. Trauma to blood causes activation of Factor XII. When Factor XII comes 
in contact with wet able surfaces like collagen it gets activated to a 
protease – Factor XIIa. Simultaneously, platelets release platelet factor 3 
which in turn contributes to the coagulation cascade. 
2. Factor XIIa activates Factor XI to XIa. This reaction needs High 
molecular weight kininogen and prekallikrein. 
3. The activated Factor XI then enzymatically cleaves Factor IX to form the 
activated Factor IXa. 
4. The activated Factor IXa, along with activated factor VIIIa, Platelet factor 
3 and platelet phospholipids end in activating Factor X to Xa. Factor VIII 
is also known as the antihaemophlic factor. 
5. This step is the same as in intrinsic pathway. The activated Factor X 
combines with Factor V to form the prothrombin activator complex.  
6. The prothrombin activator causes conversion of prothrombin too 
thrombin thereby setting the coagulation cascade into motion. 
CONVERSION OF PROTHROMIN TO THROMBIN: 
           After the formation of prothrombin activator by either the intrinsic or 
extrinsic pathway, it causes conversion of prothrombin to thrombin in the 
presence of ionic calcium. Thrombin causes polymerization of fibrin molecules 
within 10 to 15 seconds. So, the rate limiting step in coagulation process is the 
formation of the prothrombin activator and not the steps that happen beyond it.  
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Platelets also play a role in the conversion of prothrombin to thrombin as most 
of the prothrombin binds to the prothrombin receptors on the surface of the 
platelets. 
PROTHROMBIN AND THROMBIN: 
          Prothrombin is formed by the liver and it needs Vitamin K for formation. 
The normal plasma concentration is about 15mg/dl. It is constantly being used 
up in the body for coagulation process. In the presence of liver failure or vitamin 
K deficiency, prothrombin production is grossly reduced and can result in 
coagulopathy. 
 
Thrombin is the link between vascular injury, coagulation and platelet 
activation. 
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CONVERSION OF FIBRINOGEN TO FIBRIN AND CLOT 
FORMATION: 
FIBRINOGEN: 
          Fibrinogen is a high molecular protein, (MW=3,40,000) with a plasma 
concentration of 100 to 700mg/dl. It is produced in the liver and so liver disease 
can result in reduced plasma levels of fibrinogen. Because of its high molecular 
weight, little, leaks outside the blood vessels. In case of trauma, it leaks out and 
can cause clotting of tissue fluids just like plasma and blood. 
CLOT RETRACTION: 
          Within a few minutes after clot formation, it begins to contract expressing 
the serum. In this way serum differs from plasma because it cannot clot as the 
clotting factors have been depleted. The platelet themselves contribute to the 
process of clot retraction. Clot retraction is affected in case of 
thrombocytopenia. The platelets bring the fibrin molecules together. The 
contractile process within the platelets get activated and this is involved in clot 
retraction. It also releases procoagulant factors. The contraction is activated by 
thrombin and accelerated by the calcium released from the endoplasmic 
reticulum and golgi apparatus within the platelets.  
        As the clot retracts, the edges of the broken blood vessels are pulled 
together there by contributing further to complete haemostasis. 
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COFACTORS: 
  Substances required for the proper functioning of the coagulation cascade: 
 
CALCIUM 
VITAMIN K 
 Except for the first two steps of the intrinsic pathway, Calcium ions are 
needed for the activation and propagation of the entire coagulation 
cascade. In live, the levels of ionised calcium rarely become low enough 
to affect the coagulation. But after sampling, blood can be maintained in 
the liquid state by adding citrate, that binds with the ionised calcium or 
oxalate, that precipitates the calcium. 
 Vitamin K is essential for the gamma carboxylation of Factor II, VII, IX 
and X. This process is essential for the factors to bind to phospholipids 
and there by participate in the coagulation cascade. In the absence of 
vitamin K, either due to deficiency or liver disease, PIVKAs (Proteins 
formed in the absence of Vitamin K) are formed. These are defective 
proteins and do not participate effectively in the coagulation cascade. 
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REGULATORS: 
  There are four mechanisms that keep platelet activation and the 
coagulation cascade in check. Abnormalities can lead to an increased tendency 
toward thrombosis: 
 Protein C is a trypsin like peptide molecule. The gene for Protein C is on 
chromosome 2. It undergoes a lot of post translational modification at the 
amino terminal end. Thrombin activates protein C into aPC.  Activated 
protein C inhibits factor Va and VIIIa. This causes termination of the role of 
factor VIIIa in the tenase complex and the role of factor Va in forming the 
prothrombin activator complex. The net effect on the coagulation cascade is 
inhibition of further fibrin and there by clot formation. Apart from the      
anti coagulant effect, it also has cytoprotective and anti-inflammatory 
properties by binding to the endothelial protein c receptor and activating 
PAR 1. 
 Antithrombin is a serine protease that inhibits factor Xa and thrombin. The 
normal plasma concentration is 0.15 to 0.20 mg/ml. Antithrombin deficiency 
can cause thrombotic disorders. There are two types. Type 1, in which the 
level of the protein is reduced and Type 2 , in which the functional activity 
of the protein is reduced.   
  Tissue factor pathway inhibitor (TFPI) limits the action of tissue factor (TF) 
and also inhibits excessive TF-mediated activation of Factor VII and Factor 
X. 
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 Plasmin is produced from the plasminogen, a zymogen produced in the liver. 
While in circulation, plasminogen adopts a closed conformation. After 
binding to clots it adopts an open conformation and can be activated to 
plasmin by a variety of factors, the most important of which is Tissue 
plasminogen activator. Plasmin deficiency, which is rare in humans, can 
cause thrombosis. 
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ROLE OF APC AND PLASMINOGEN: 
  
 
Blue arrows – Stimulation 
Red arrows - Inhibition 
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MUTATIONS IN HAEMOPHILIA : 
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PRENATAL DIAGNOSIS AND CARRIER DETECTION :  
Prenatal diagnosis can be suggested to woman those who are related to 
obligate Haemophilia carriers and known Haemophiliacs. Germ line mutations 
have different implications when it occurs in the grandfather and the mother. 
Prenatal diagnosis can be done using cells obtained during amniocentesis done 
at 16 weeks of gestation. If the foetus is a female little is the concern as carrier 
females rarely have bleeding manifestations. In case of a male foetus, the 
diagnosis can be made by DNA analysis of the cells. Termination or 
continuation of the pregnancy to term is left to the decision of the parents. 
DNA based methods are preferred for carrier detection. Studies identified 
the causative mutation in 90% of patients with mild and moderate haemophilia 
A but only 50 to 60% of patients with severe disease. Direct gene analysis for 
the inversion of intron 22 is recommended in all females suspected to be 
carriers. 
The analysis is performed in the eleventh to twelfth week of gestation 
either by amniocentesis or chorionic villus sampling.  
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CLINICAL PRESENTATION 
Clinical presentation of Haemophilia A and B are indistinguishable. Both 
are very similar in their presentation.  
Severe Haemophilia refers to factor levels less than 1% of normal or less 
than 0.01u/ml. They present in early infancy with spontaneous haemorrhage. 
Frequent spontaneous hemarthroses and haemorrhage are common and they 
require frequent factor replacement. 
Moderate haemophilia have factor levels  between 1 to 5% of normal. 
They present with increased bleeding after a minor trauma and surgery. 
Spontaneous bleeds are rare and occasionally they present with spontaneous 
hemarthroses. 
Mild haemophilia refers to factor levels of 6 to 30% of normal. These 
patients bleed secondary to surgery and rarely do they present with spontaneous 
hemarthroses. 
Some of the severe Haemophiliacs do not manifest the severe bleeding 
and they have been identified to have the Factor V Leiden mutation.  
The bleeding episodes in Haemophiliac patient is intermittent. Some do 
not bleed for weeks together. Death from bleeding occurs only in intracranial 
haemorrhage.  
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Most carriers have factor levels greater than 50% and do not have 
bleeding manifestations. Those with factor levels less than 50%, due to 
extremely imbalanced X chromosome mutation,  have bleeding post trauma or 
surgery. Factor VIII levels should be checked in all Haemophilia carriers. 
The most common presenting clinical symptom in moderate and severe 
haemophilia is intra articular and intra muscular bleeds. These symptoms tend to 
occur only after the child begins to ambulate. In fact, the most common 
presenting manifestations of Haemophilia A and B in one series of patients were 
soft-tissue bleeds in 41%, bleeding associated with intramuscular injections and 
surgery in 16%, and oral bleeding from tongue or lip biting in 11%,14% of 
which were severe enough to require transfusion of packed red blood cells1.  
PATIENTS WITH SEVERE DISEASE HAVING MILD 
MANIFESTATIONS – REASONS: 
1. The Leyden phenotype of Haemophilia B is characterized by severe 
haemophilia in childhood that becomes mild after puberty.  The mutation 
is at the nucleotide 20 promoter region and it disrupts the HNF-4 binding 
site but not the overlapping site for androgen binding. This might explain 
the recovery after puberty5. 
2. Coinheritance of Leiden V and other prothrombotic states occurs in a 
small percentage of Haemophiliacs and this might counteract the bleeding 
from decreased factor levels. Patients with such coinheritance experience 
fewer bleeds and also have a later onset of first bleed5. 
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INTRAPARTUM COMPLICATIONS: 
A study of the modes of delivery and peri-natal complications in affected 
male babies shows that the risk of intracranial bleed is less in normal delivery. 
(<3.8%)3. The risk of subgaleal and cephalic hematoma increases with vacuum 
delivery. Caesarean section does not eliminate the risk of intracranial 
haemorrhage. Forceps delivery and prolonged labour increase the risk of 
intracranial bleeds. However, the use of scalp electrodes and intrapartum blood 
sampling for affected neonates does not increase the risk of bleeds in the 
neonate1.  
Seizures are common during the acute intracranial bleed episode. 
Psychomotor complications and cerebral palsy can occur as long term 
complications. Most episodes of intracranial bleed in newborns occur in 
sporadic cases and with the use of vacuum apparatus. In a European study, 
involving 508 children born with Haemophilia A or B, intracranial bleeds 
occurred in 18 (3.5%) within the first 28 days of life5.  
 
Vaginal delivery with forceps or assisted vacuum must be avoided in 
woman who are known carriers of Haemophilia and are known to be pregnant 
with a male child.  
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CIRCUMCISION AND BLEEDING:  
50% of undiagnosed haemophiliacs have excessive bleeding during 
circumcision that can be stopped with factor infusion. Such excess bleeding 
occurs in less than half of the affected infants. Thus, failure to bleed does not 
eliminate the presence of Haemophilia in that patient. 
 
AGE OF BLEED ONSET:   
Children with severe haemophilia become symptomatic within the first 2 
yrs of life. In a study, the mean age of first bleed leading to the diagnosis of 
Haemophilia was at 0.9 yrs of age, in the absence of any prothrombotic factor 
coinheritance.  
In the presence of prothrombotic factors, the mean age for diagnosis was 
late and was around 1.6 years of age5.  However some patients do not bleed 
before the age of five. Joint bleeds are very common and early diagnosis would 
help to prevent the joints from hemarthropathy. 
The age of diagnosis in mild and moderate Haemophilia is later than that 
for severe haemophilia. In a study of 140 boys from Sweden, the mean age of 
diagnosis of Moderate and severe disease was found to be 22 and 9 months 
respectively5. 
Mild haemophilia without family history can go undetected for a very long 
period of time, as about one third of patients have very few bleeding episodes. 
 
  
41 
 HEMARTHROSES 
 HEMATOMAS 
 PSEUDO TUMORS 
 HEMATURIA 
 NEUROLOGICAL COMPLICATIONS 
 MUCOUS MEMBRANE BLEEDS 
 POST SURGICAL BLEEDS 
HEMARTHROSES: 
Hemarthroses is the most common bleeding manifestation in severe 
haemophiliacs contributing to about 75% of the bleeding episodes. 
Anatomy of the synovium favours bleeding, It has numerous cells and 
abundant capillaries that lie beneath the synovial layer. These capillaries are 
susceptible to damage during mechanical trauma associated with the daily use of 
joints. The joints involved in decreasing order of frequency are knee, elbow, 
ankle, shoulder, elbow and hip. Hinge joints are more commonly affected than 
ball and socket joints.  
Hemarthroses might produce an aura of discomfort that gradually progresses 
to cause joint enlargement and excruciating pain. The joint becomes swollen, 
warm and tender with decreased range of movement. Patient might have a mild 
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fever during the bleed. However, sustained fever indicates an infected joint. 
When bleeding stops, the blood is reabsorbed in a couple of days. If the bleed is 
treated early and the joint is not affected chronically, pain subsides in 6 to 8 
hours and disappears in 12 to 18 hours. However, repeated bleeding into the 
joint causes articular destruction and leads to haemophilic arthropathy. Once 
chronically affected it may be difficult to distinguish the pain of degenerative 
arthritis from the pain of bleeding.   
The synovium becomes thickened and folded leading to repeated bleeds in 
the same joint causing the so called target joint. The joints most often involved 
are the weight bearing joints, knee and ankle. Bleeding into a joint with 
thickened synovium causes less pain than bleeding into a normal synovium.  
In the presence of fever, leukocytosis and other systemic manifestations the 
probability of an infected hemarthroses should be considered. Rapid diagnosis is 
a must as infection in such joint progresses rapidly causing loss of joint space 
and architecture. The joint should be aspirated under strict aseptic techniques 
and factor replacement should be given. Chronic haemophilic arthropathy is 
painful with weight bearing but the pain subsides or disappears once the joints 
become ankylosed. Muscle atrophy around the joint can lead to increased 
inability and increased bleeding from the loss of cushioning effect provided by 
the muscles. Patients with factor VIII or IX deficiency with levels greater than 
20% of normal rarely develop haemophilic arthropathy even if they have 
experienced previous bleeds1. 
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Socio economic status and other health effects have an influence on the 
morbidity of haemophilic arthropathy. Obesity is common among 
haemophiliacs because of repeated bleeds and sedentary lifestyle. This further 
has an effect on the range of movements of the joints.  
Haemophilic arthropathy – Chronic effects of repeated knee bleeds
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Radiographic stages of haemophilic joint :  
 
 
Stage 0 – Normal joint 
Stage 1 – fluid in the joint 
Stage 2 – Osteoporosis and epiphyseal overgrowth – Fig A 
Stage 3 – Subchondral bone cysts – Fig B (arrowheads) 
Stage 4 – Prominent bone cysts with marked narrowing of joint space – Fig C 
(arrows) 
Stage 5 – Joint obliteration with epiphyseal overgrowth. 
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HEMATOMAS: 
Hematomas can occur in the subcutaneous plane or into the muscle. They 
are very characteristic of clotting factor deficiencies. Hematomas, with bleeding 
into the muscles occur most commonly in the quadriceps, iliopsoas and forearm. 
Smaller hematomas resorb without any residual defects. If large and in severely 
affected patients subcutaneous bleeds can dissect into the muscle plane. 
Retroperitoneal hematoma:  
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Retroperitoneal hematomas can dissect through the diaphragm into the 
chest and neck and compromise the airways. They might cause ureteral 
obstruction and compromise renal function. An abdominal hematoma can 
rupture and drain into the colon which is very rare and most often fatal. 
Iliopsoas bleeds tend to be large and compromise neurovascular structures 
causing compartment syndrome. These bleeds can be localised with ultrasound 
and require larger doses of factor VIII. 
Bleeding around airways is an emergency and must be treated 
immediately with large doses of factor VIII to prevent compromise of the 
airways.  
  Untreated hematomas can lead to pseudotumor formation, with the 
formation of a fibrous membrane around the hematoma.  
Patients with Haemophilia can develop hematoma of the bowel wall and 
present as appendicitis, intestinal obstruction or intussusception. The diagnosis 
of “pseudo  appendicitis” can be made with CT scan.  
PSEUDOTUMOR: 
Pseudotumor is also known as blood cysts. There are three types of 
pseudotumor. 
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Type 1 : Simple cyst; confined by the tendinous attachment within the fascial 
muscle 
Type 2: Simple cyst that compromises the vascular supply to the adjacent bone 
and periosteum resulting in bone resorption and cyst formation 
Type 3: Subperiosteal bleeding resulting in separation of the periosteum from 
the bone cortex. 
Pseudotumors contain either a serosanguineous fluid or brownish material 
surrounded by a fibrous membrane. They cause pain only when the collection is 
rapid or when they compress nearby neurological structures. Pseudotumors tend 
to expand over years together and can become multiloculated. They can reach a 
stage where they become inoperable. Sinus tract formation from a pseudotumor 
is a risk for increased infections.  
Most common sites for pseudotumor formation is in the lower limb but 
they can occur at other sites too. Small joints of the hands can be involved in 
younger patients.  
MRI and CT help in diagnosis. Needle biopsy of the pseudotumor should 
be avoided for fear of bleeding and infection.  
The only definitive treatment is complete excision. If incompletely 
removed the pseudotumor tends to reform. 
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Pseudotumor of the fibula: 
  
 
HEMATURIA: 
Hematuria is frequently seen in severe haemophiliacs. Colour of the urine 
can vary from red to brown depending on the rate of the bleeding. Bleeding can 
occur from anywhere along the genitourinary tract from the renal pelvis till the 
bladder. Patients can experience colicky pain if clots obstruct the ureter. 
Bleedings tends to last from days to weeks depending on the severity of the 
bleed. If the bleeding does not stop within a weeks’ time and if the patient is 
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symptomatic, Factor replacement must be given. A search for structural cause of 
bleeding should also be made if the bleeding is prolonged and does not subside 
with factor replacement. 
 
NEUROLOGICAL COMPLICATIONS: 
Intracranial bleed is the most severe of all complications. The bleed can occur 
spontaneously but most commonly occurs after a trivial trauma. Symptoms 
might occur soon after the bleed or it might be delayed. Suspicion of an ICH 
should arise when a haemophilia patient complains of severe headache. 
Treatment should be started immediately when there is a suspicion of 
intracranial bleed without waiting for imaging studies.  
Bleeding into the spinal cord is very rare and can result in paraplegia. 
Epidural bleeding compressing the cord is more common. Muscle hematomas in 
the periphery can result in peripheral nerve compression. Femoral nerve 
compression by iliopsoas bleed is most common and can result in sensory loss 
over the anterior and lateral thigh, weakness and atrophy of the quadriceps. 
Ulnar nerve is the next most commonly involved peripheral nerve.   
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Intracranial bleed in severe hemophilics: 
 
MUCOUS MEMBRANE BLEEDS: 
Mucous membrane bleeds in the form of epistaxis and hemoptysis is 
common in haemophiliacs. Peptic ulcer disease is more common in 
Haemophilia A when compared to the general population.  
Occult blood loss in urine or stools might contribute to the iron deficiency 
seen in these patients and was recorded so in a study conducted in the university 
of Florida2. 
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POST SURGICAL BLEED: 
Severe haemophilic patients need to be treated with factor preoperatively 
and post operatively. Mild or moderately affected patients are at times 
diagnosed only after bleeding occurs from the surgical site. Wound healing is 
poor in such patients. Appropriate Factor VIII replacement can prevent intra 
operative and postoperative bleeding.  
Dental extraction is the most common surgical procedure done on 
haemophilia patients. Loss of permanent teeth causes more bleeding than loss of  
deciduous teeth. 
BLEEDING IN CARRIERS:  
A wide range of factor levels have been observed in normal people as 
well as heterozygous carriers of Haemophilia A or B. Extreme lyonisation can 
cause excessive bleeding in a female carrier.  
Factor levels are independent of the bleeding severity and vary from 
person to person within the same family. Clotting factor levels should be 
obtained in all carriers prior to a medical or surgical intervention in order to 
assess the bleeding risk involved. 
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COMPLICATIONS IN HAEMOPHILIA 
There are three major complications that can occur in haemophiliacs, 
 Joint destruction and abnormalities due to hemarthroses 
 Blood borne infection transmission 
 Development of Inhibitor antibodies 
HEMOPHLIC ARTHROPATHY: 
There are several factors that contribute to the development of 
arthropathy. The most important among them would be the deposition of iron in 
the synovium and the development of synovial fibrosis that leads to contracture 
formation. The patient has extreme pain and limitation of the range of 
movement.    
Primary prophylactic treatment with factor VIII or IX dramatically 
reduced the incidence of arthropathy and increased the quality of life. A 
randomized control trial comparing three times per week prophylactic dosing 
against the on-demand dosing showed that prophylactic dosing was superior to 
on-demand dosing schedule.  
The relative risk of MRI detected joint damage with episodic therapy as 
compared with prophylaxis was 6.1 (95% CI 1.5-24)5. Orthopaedic 
complications still remain a major issue as on-demand treatment is still the 
treatment method followed in India. 
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The completed Joint Outcome Study in the United States has 
demonstrated that prophylaxis with Factor VIII at 25-35 units per kilogram body 
weight every other day is superior to intensive on-demand (eg, 40 units/kg 
initially, then 25 units/kg at 24 and 72 hours) factor replacement therapy in 
preventing joint disease in previously pristine joints at age six years. The 80 
percent lower incidence of pristine joints in the on-demand arm was confirmed 
by validated physical exam and radiographic scoring as well as by follow-up 
magnetic resonance imaging of ankles, knees, and elbows in the 66 children 
randomly assigned between the two arms of the study. 5. 
 
INFECTION: 
 
The incidence of infection has dramatically reduced with the advent of 
recombinant products and use of intensive donor screening and virucidal 
techniques. Patients treated with older factor VIII or IX concentrates are at 
higher risk of developing Hepatitis B, C and D or HIV infection. Co-infection 
with HCV and HIV has a bad prognosis as far as the liver derangement is 
concerned. These people tend to respond poorly to treatment.  Since the mid 
1980s, no HIV infection has been reported with the use of anti haemophilic 
factor with advanced virucidal techniques. 
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Other rare infections that can be transmitted through the use of anti 
haemophilic factors are parvo B19, Creutz feld Jacob disease and the new 
variant of CJD. CJD and nvCJD are transmissible spongiform  
encephalopathies.  
 
DEVELOPMENT OF INHIBITORS:  
The most important complication of Haemophilia is the development of 
inhibitors to factor VIII or IX.  
 
HAEMOPHILIA A AND INHIBITORS: 
 
The development of inhibitors is more common with Haemophilia A than 
B. The severe Haemophilia A phenotype is most commonly due to a null 
mutation. A null mutation refers to the complete absence of the protein thereby 
predisposing to the development of inhibitors. In severe disease 30%, moderate 
disease 3% and in mild disease 0.3% tend to develop inhibitors.  
Genetic and environmental factors play a role. The presence of a first degree 
relative with Inhibitors increases the risk of inhibitor development three fold in 
the patient.  
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Mutations that play an important role in inhibitor formation include, 
inversion of intron 22, large deletions affecting more than one domain and 
nonsense mutations involving the light chain. There is a protective factor against 
inhibitor development when prophylactic treatment is started at an early age. 
Inhibitor development is seen more in patients exposed to continuous factor 
infusions as seen during surgeries. As far as the type of factor is concerned, the 
recombinant factor VIII tends to be more immunogenic when compared to the 
old low/intermediate purity plasma derived factor VIII. The potential causes for 
recombinant factor VIII being more immunogenic would be the formation of 
neo antigens during manufacturing process and the absence of von willebrand 
factor.  
Normally when factor VIII is secreted, it is non-covalently bound to vWF 
via the light chain, particularly through interactions with a3 and the C2 domain. 
Upon thrombin activation, factor VIIIa dissociates from VWF and via the C2 
domain, which is no longer bound by VWF, binds to phosphatidylserine on the 
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platelet membrane. Inhibitors interrupt this process through a number of 
different mechanisms1. 
With the development of inhibitors, the frequency of bleed does not 
increase but the patient tends to respond poorly to treatment and develop 
damaged joints that bleed more frequently. In the worst scenario, a mild 
Haemophilia patient can become a severe Haemophiliac when the inhibitors 
react with the reminiscent factor VIII and inactivate them. Any Haemophilia 
patient who fails to respond to treatment should be evaluated promptly for the 
development of inhibitors. 
The diagnosis is made by using the Bethesda assay. It was developed in 
1975 and it depends on the ability of the patient’s plasma to inactivate factor 
VIII in the normal plasma. The result is express  
HAEMOPHILIA B AND INHIBITORS: 
The incidence of inhibitors in Haemophilia B is less than that in 
Haemophilia A. The other differences include the possibility of anaphylactic 
reaction on infusing factor IX concentrates, lesser response to immune tolerance 
therapy and increased incidence of nephrosis with immune tolerance therapy. 
Just like Haemophilia B, the incidence of inhibitors increases after factor IX 
infusion. 
Similar to Haemophilia A, inhibitors should be suspected when treatment 
failure happens. Since anaphylactic reactions are common, patients with high 
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risk mutations should be screened at regular intervals for the development of 
inhibitors. 
Treatment is similar to that of Haemophilia A with inhibitors. 
Development of nephritic syndrome during immune tolerance induction is a 
major concern and regular urine analysis should be undertaken in this subset of 
patients. The nephritic syndrome that develops responds poorly to steroids 
making treatment further complicated. 
 
DIAGNOSIS AND DETECTION OF CARRIERS 
Diagnosis begins with review of family history especially on the maternal 
side. 
The mother can be identified as a carrier when a family history of 
bleeding is present. One third of patients have a negative family history. Hence, 
the lack of family history does not rule out haemophilia. 
REASONS FOR NO FAMILY HISTORY: 
 The patient might have spontaneous mutations involving factor VIII gene. 
25 to 33 % of cases have spontaneous mutations5.  
 Neonatal deaths or the passage of the trait through successive female 
carriers might give a negative family history5. 
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Symptomatic haemophilia is well documented in female. The possible 
reasons include, 
 Unequal and early inactivation of the X chromosome 
 Mating between an affected male and a carrier female produces 
homozygous disease in one half of the female offspring. 
 An abnormal karyotype as in Turner’s syndrome 
 
1. SCREENING TESTS 
2. SPECIFIC ASSAYS 
3. DISTINCTION FROM VON WILLEBRAND 
 
 
SCREENING TESTS: 
Three initial tests should be performed in patients presenting with unknown 
bleeding disorder. 
1. Platelet count 
2. Prothrombin time 
3. Activated partial thromboplastin time 
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CAUSE OF PROLONGED PT AND OR aPTT: 
 
A normal PT, Platelet count and  a prolonged aPTT are characteristic of  
Haemophilia A and Haemophilia B. The test is abnormal in those with factor 
levels less than 30%. In mild diseases the aPTT may be normal. So, in case of a 
mild undiagnosed bleeding disorder with normal lab values factor assays should 
be done.  
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Other disorders that prolong the aPTT but not the PT include acquired 
inhibitors to factor VIII and IX. A similar pattern is also seen in patients with 
antiphospholipid antibodies but they tend to thrombose rather than bleed. 
In the absence of inhibitor which does not occur in patients not treated with the 
factor, the elevated aPTT should be correctable with normal plasma.  
 
SPECIFIC ASSAYS: 
Specific assays for factor deficiency that result in isolated prolonged 
aPTT are done in the order of statistical significance – VIII, IX and XI. There 
are two methods to perform the assay for factor VIII – one stage method and 
two stage method. 
The one stage method is preferred as it easier and cheaper. But there are 
chances of false negatives if only the one stage method was used for diagnosis.  
Chromogenic substrate assay is another method for identifying factor VIII 
levels. The above test depends on the Factor VIII mediated activation of factor 
X.  
Other methods that have developed include, immunoradiometric methods 
and enzyme linked immunoabsorbent assay. 
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DISTINCTION FROM VON WILLEBRAND DISEASE: 
Ristocetin cofactor assay is the most sensitive test to identify von 
willebrand disease. It is difficult to perform. Von willebrand is an acute phase 
reactant and its level increases in times of stress like pregnancy, fever and 
hormone replacement. In type 2N von willebrand disease, there is a defect in the 
binding site for factor VIII and bleeding results from the low levels of factor 
VIII. Type 2N von willebrand is a diagnostic difficulty. It is one differential 
diagnosis of mild Haemophilia. Type 2N von willebrand disease should be 
suspected in any female with a low level of Factor VIII.   
DIFFERENTIAL DIAGNOSIS 
 Von Willebrand disease 
 Platelet disorders – eg. Glanzmann thromasthenia 
 Clotting factor deficiency – V,VII,X or XI 
 Acquired haemophilia 
Haemophilia is diagnosed with the presence of a positive family history, 
prolonged bleeding, hemarthroses and spontaneous soft tissue bleeds. The last 
two features differentiate it from von Willebrand disease in which hemarthroses 
and soft tissue bleeds are generally rare except in case of severe type 3 disease. 
The basic defect in vWd is the reduced activity of von Willebrand factor which 
acts as a carrier for the factor VIII molecule in vivo. In the absence of the 
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carrier, the half life of factor VIII is reduced and it is rapidly cleared from the 
circulation. The main differentiating factors are a prolonged bleeding time, 
reduced von Willebrand antigen assay and abnormal ristocetin induced platelet 
aggregation. vWd – Normandy variant is difficult to distinguish from 
Haemophilia A. In the Normandy variant, vWd levels are normal but factor VIII 
levels are low. Factor VIII is produced normally but there is a failure in the 
incorporation of factor VIII into the von Willebrand factor. 
Differentiating Haemophilia A and B is impossible from history and physical 
examination. Factor assay is a must. Similarly, factor assays are needed to 
differentiate between Haemophilia and deficiency of other clotting factors. 
Acquired Haemophilia is seen in autoimmune syndromes, in which inhibitors 
to Factor VIII develop spontaneously. 
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TREATMENT 
Treatment of Haemophilia includes  
 Preventive measures 
 Treatment with factor replacement either as on-demand or prophylaxis  
 Treatment of complications 
 
PREVENTIVE CARE: 
Circumcision:  
Approximately 40% of undiagnosed haemophiliacs bleed in association 
with circumcision. For this reason, male babies born to female carriers should 
be deferred from the procedure. Whether circumcision can be carried on in this 
group is still a controversy. Fibrin glue can be used. It reduces the bleeding and 
the high cost involved in the treatment of haemophilia. 
 
Immunisation: 
The routine immunizations given intramuscularly in normal people can be 
given as deep subcutaneous in haemophiliacs. Smallest gauge needle must be 
used. Pressure and ice packs must be applied for three to five minutes at the 
injection site in haemophiliacs. Intramuscular injections are contraindicated in 
Haemophilia. Hepatitis B vaccine should be given to all infants affected with 
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Haemophilia. Hepatitis A can be given at one year of age. Inactivated polio 
vaccine should also be given. 
 
Dental Care: 
Proper dental care should be advocated. The patients should be taught 
about the importance of routine cleaning and maintenance of oral hygiene. Early 
and proper toothbrush training should be given to the children. 
Counselling and Education: 
Genetic and Psychosocial counselling should be given to the patient as 
well as the family members. About 30% of the cases have no family history and 
in that case proper education about the disease and its complications is very 
important. Normal socialization and development should be encouraged. 
Exercise and Athletic participation: 
A regular exercise regimen should be introduced into the life of 
haemophiliacs. Most of the Haemophilia patients, for fear of bleed, tend to 
become sedentary and end up with obesity which further increases the risk of 
bleeds in the weight bearing joints. With the advent of prophylaxis all over the 
world, The World federation for Haemophilia advocates regular exercise 
regimen. Proper communication between the parent, patient and staff is very 
important. 
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REPLACEMENT THERAPY: 
The cornerstone to the management of Haemophilia is the factor 
transfusion. The dosing is standard but the length of the treatment, choice of 
product depends on expert individual decision. Guidelines for replacement have 
been established but the minimum factor level required for haemostasis has not 
been established. For minor bleeds it’s enough if the factor level is raised to 25 
to 30% of normal. In case of major bleeds the factor levels should be raised to 
50% of normal and in life threatening bleeds and surgery the factor levels 
should be maintained at 100%. Each unit of Factor VIII per kg of body weight 
tends to increase the factor level by 2%. Therefore, 1750 units of factor VIII 
will raise the factor level by 50% of normal. The decrease in factor level post 
transfusion depends on the pharmacokinetics of the factor. Half life of factor 
VIII is eight to twelve hours. Half of the initial dose is repeated every eight 
hours to maintain the desired factor level.  
Factor VIII can be derived from the plasma or can be recombinant – derived 
from cell lines genetically engineered to express large amounts of factor VIII. 
Plasma products are stratified based on purity and the recombinant products are 
characterized by their generations. Both can be given intravenously. Solvent 
treated fresh frozen plasma can be given in the absence of factor and the 
transmission of viral diseases is very much reduced.  
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 Intermediate purity concentrates contain 6-10units/mg of protein 
 High purity products contain 50 units/mg of protein 
 Ultra high purity products include the monoclonal antibody affinity- 
purified plasma derived concentrate and recombinant factor. 
FIRST GENERATION RECOMBINANT FACTOR VIII: 
These recombinant factors are derived from the cell cultures of 
transfected hamster derived cell lines and need no further purification. The 
human albumin, added for stabilization purposes, contributes to the risk of viral 
contamination.  
SECOND GENERATION RECOMBINANT FACTOR VIII: 
This recombinant factor does not contain albumin. Instead, sucrose is 
added for stabilization. The protein of factor VIII lacks the B domain (mutated 
protein). The B domain of factor VIII is not needed for coagulation and deleting 
it increases the stability of the smaller molecule.  
THIRD GENERATION RECOMBINANT FACTOR VIII: 
These have no added albumin or added protein at the end of preparation. 
LONGER HALF LIFE PREPARATIONS: 
Factor VIII with longer half life is desirable as it would decrease the 
frequency of dosing intervals in Haemophilia patients. The two strategies under 
study for prolonging the half life of factor VIII are – fusion with the Fc portion 
of immunoglobulin and reconstitution with pegylated liposomes. 
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Binding of the factor VIII to the Fc portion of immunoglobulin results in 
binding to the neonatal Fc receptor present on many adult cells. This binding 
prevents the degradation of factor VIII thereby increasing its half life about 1.5 
to 2 fold. 
INVESTIGATIONAL STRATEGIES: 
A potentially exciting advance is to develop a product that would bind 
both Factor X and IXa, thereby bringing the two substrates together and 
bypassing the cofactor function of Factor VIII. This interesting idea is still under 
study. 
The choice of product depends on the purity, safety and cost. Purity and 
viral safety are utmost important to both, the treating physician and the patient. 
Ultrapure products are preferred in HIV coinfected Haemophiliacs as they 
stabilize the CD4 counts. 
FACTOR IX PRODUCTS: 
In the 1970s and 80s, Prothrombin complex concentrate was used. It was 
produced by the co-purification of Vitamin K dependant cofactors. This co-
purification resulted in the activation of Factor VII to VIIa resulting in an 
increase in thrombotic complications. PCCs are no longer preferred because of 
the increased thrombosis risk. Instead, purified human derived or recombinant 
factors are used. 
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PURIFIED FACTOR IX: 
Chromatographic partitioning and monoclonal antibody affinity 
purification are the techniques used to purify Factor IX. They are further 
subjected to viral inactivation processes. 
 
RECOMBINANT FCATOR IX: 
It is genetically engineered by inserting the gene for factor IX into a 
Chinese hamster ovary cell line. It has no added albumin and is safe in the 
treatment of patients with previously treated and untreated Haemophilia B. Half 
life of recombinant factor is about 16 to 17 hours. 
 
 
LONGER ACTING PRODUCTS: 
Factor with longer half life are preferred as it would reduce the dosing 
intervals. As with Factor VIII, binding of factor IX to Fc portion of 
immunoglobulin increases the half life about 3 to 5 fold. There are other studies 
investigating the use of Factor IX fused to pegylated liposomes or albumin. 
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DOSING: 
Early treatment of bleeding episodes with appropriate dose of factor will 
reduce the duration of bleed and prevent further complications.  It also reduced 
the tendency to re-bleed.  
Several plasma products are available for raising factor levels. The major 
disadvantage of plasma is that large volumes need to be infused for maintaining 
very low factor levels. It is very difficult to achieve haemostasis with plasma 
infusion. Cryoprecipitate can be used. It contains 80 units of factor in 10ml. The 
disadvantages are the dosing of factor VIII can only be estimated and the 
cryoprecipitate has to be stored in a frozen state.  
In case of Haemophilia B, in older days, PCC was used. PCC contains 
vitamin K dependant factors including protein C and protein S. A few of the 
factors like VII IX and X become activated and increased incidence of 
thrombotic events have been reported including DIC.  
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To achieve 100% factor level, that is, 1u/ml, 3500 units of factor VIII is 
required. However, the site and the severity of bleed determines the dosing in a 
particular patient. Factor VIII can be given as infusion. After a loading dose, 
about 150 to 200 units per hour can be given as infusion. Factor levels can be 
monitored regularly using venous sampling. 
The dose calculation for factor IX is different from that of Factor VIII as 
the intravascular recovery of factor IX is only 50%. This is probably due to the 
binding of Factor IX to collagen type IV in the vessel wall. The dose of factor 
IX can be estimated by assuming that 1 U of factor IX per kilogram body weight 
increases circulating factor IX by 1 percent of normal or 0.01 U/ml. Thus, to 
achieve 100 percent of normal (using only highly purified factor IX products) in 
a severely affected patient, 100 U of factor IX per kilogram body weight should 
be given as a bolus, followed by half this amount every 12 to 18 hours. 
Prophylactic therapy can be attempted in Haemophilia B and the dosing is 20 to 
40 units/kg twice a week.  
HAEMOPHILIA A AND INHIBITORS: 
The most important complication of Haemophilia is the development of 
inhibitors against factor VIII.  
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Risk Factors: 
1. Disease severity – 80% of patients with Inhibitors have factor VIII less 
than 1% 
2. Exposure to factor concentrates – majority develop inhibitors after 
exposure <90 days. 
3. Method of purification of Factor VIII concentrate 
4. Genetic factors : 
Family history of inhibitors 
Negative association with HLA Cw5 antigen 
Molecular defects: inversion and crossing-over defect in intron 22, gene 
deletions, and nonsense point mutations resulting in patients without 
factor VIII antigen. 
The inhibitors against factor VIII are antibodies that belong to the IgG4 
subclass. Most commonly these antibodies are directed against the A2 and C 
domain of Factor VIII. Early diagnosis of factor VIII inhibitors is important. 
The diagnosis is most often made when a patient does not respond to Factor 
VIII infusions.  The inhibitors are detected using a common assay called the 
Bethesda assay. A mild modification of this is the Nijmegen assay.  
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HIGH RESPONDERS: 
High responders are defined as patients whose inhibitor titre is higher 
than 10 Bethesda units (BU) at baseline or whose initial inhibitor titre is less 
than 10 BU but rises to greater than 10 BU after administration of factor VIII. 
Thus, high responders who are not treated with factor VIII for long periods may 
have a sustained high level of inhibitor, or they may have a very low to 
undetectable level of inhibitor until they are challenged with factor VIII3. 
Major bleeding episodes in high responders with initial inhibitor levels 
<10BU can be treated with high doses of either human factor VIII or porcine 
Factor VIII. This high will overcome the inhibitors. Though factor eight bypass 
activity can be used, it is not as reliable as factor VIII and the effects cannot be 
monitored by a reliable blood investigation. 
In major bleeds factor VIII is given in a dose of 10,000 to 15,000 units 
stat followed by 1000 units per hr infusion with frequent monitoring of factor 
VIII levels.   
In high responders with inhibitor less than 10BU, who experience minor 
bleeds, the preferred treatment would be factor eight inhibitor bypass activity or 
Recombinant factor VIIa. The dose of Recombinant factor VIIa is 90 to 
120mcg/kg that can be repeated at two to three hour intervals.   
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Patients with inhibitors >10BU rarely respond to high levels of factor 
VIII. In this case the treatment of choice would be either recombinant factor 
VIIa or factor VIII inhibitor bypass activity for both minor and major bleeds. 
LOW RESPONDERS: 
Low-responder patients are arbitrarily defined as patients whose inhibitor 
titre is less than 10 BU even after challenge with factor VIII. For major bleeds 
high dose of factor VIII is recommended. In case of minor bleed, recombinant 
factor VIIa or FEIBA is preferred as most low responders become high 
responders when challenged with repeated doses of factor VIII. 
IMMUNE TOLERANCE INDUCTION: 
The most promising approach to the eradication of inhibitors is the 
immune tolerance induction. This involves the daily expose of these patients to 
factor VIII. Both low dose and high dose regimens have been tried. Bleeds that 
happen during the immune tolerance period are treated with factor VIII inhibitor 
bypass activity. 
Other immunosuppressive drugs, including cyclosporine and rituximab 
have been tried to eradicate the factor VIII inhibitors. However, these seem 
more promising in cases of acquired antibodies, in which case the antibodies are 
autoantibodies rather than alloantibodies as seen in Haemophilia patients. 
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IMMUNE 
TOLERANCE 
PROTOCOL 
DOSE RESPONSE 
High dose regimen 100 U/kg factor VIII two 
times per day until 
antibody reaches 1 
BU/ml, then 150 U/kg 
factor VIII per day until 
factor VIII half-life is 
normal 
In 16 of 21 patients, titre 
fell to <1 BU/ml 
Low dose regimen 50U FVIII/kg/day 9 out of 12 responded 
Netherlands protocol 25U FVIII/kg/day 11 out of 18 responded 
 
OTHER TREATMENT OPTIONS IN HEMOPIHLIA A: 
DESMOPRESSIN: 
Desmopressin is effective in mild to moderate haemophilia. Severe 
Haemophiliacs do not respond. The levels of Factor VIII were found to increase 
in normal as well and mild and moderate haemophilia after infusion. The dose is 
0.3mcg/kg body weight and the factor level increases 30 to 60 min after 
infusion. A concentrated nasal spray can be used at a dose of 150mcg in each 
nostril. However, the response to desmopressin should be checked before a 
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bleed as in certain instances mild and moderate haemophilia patients might not 
respond. Tachyphylaxis can happen with repeated administration of 
desmopressin. 
ANTIFIBRINOLYTIC THERAPY: 
Antifibrinolytics like epsilon aminocaproic acid and tranexamic acid can 
be used as adjuvant in cases of mucosal bleeds. They are contraindicated in the 
presence of hematuria. The dose of EACA is 4 to 5gms stat followed by 1gm/hr. 
Tranexamic acid can be given as 1g every fourth hourly. 
 
FIBRIN GLUE: 
Fibrin glue is also known as fibrin tissue adhesive. It contains a mixture 
of fibrinogen, thrombin and factor XIII and can be applied topically to the injury 
site. It is most commonly used as an adjunctive to dental procedures. 
 
LIVER TRANSPLANTATION AND GENE THERAPY: 
Liver transplantation has been done successfully in patients with 
Haemophilia and has resulted in complete cure in haemophilic patients.  
Gene therapy is under study and so far the results have been poor with the level 
of factor rise being very less and the level remained elevated only for a month.  
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FACTOR IX AND INHIBITORS: 
When the inhibitor titre is less than 10BU, it can be overcome with high 
doses of factor IX. In case of acute bleeds in patients with inhibitor levels 5 to 
10 BU/ml should be treated with same factors used to bypass the activity of 
factor VIII inhibitor. Recombinant factor VIIa can be used in the dose of 90 to 
120 mcg/kg ever 2 to 3 hrs. 
Induction of immune tolerance can be tried with daily dosing of purified 
factor IX. Anaphylaxis and nephritic syndrome are two major complications. 
Patients who experience these complications must be treated with recombinant 
factor VIIa.  
GENE THERAPY FOR HAEMOPHILIA B: 
One of the interesting approaches to gene therapy for Haemophilia B has 
been the introduction of an AAV vector containing the cDNA of factor VII, 
which, when secreted, becomes activated.122 When factor VIIa is expressed in 
Haemophilia B mice, even at low levels, the animals experience fewer bleeding 
episodes. No thromboembolic side effects were noted. Although gene transfer 
trials for haemophilic patients currently are suspended, ongoing studies of new 
vectors and in animal models of Haemophilia are encouraging. 
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MATERIALS AND METHODS 
This study was done at Government Royapettah Hospital, Chennai for a 
period of six months from April 2014 to September 2014. The study was 
performed after procuring informed written consent from all the participants 
involved.  Clearance was obtained from the Ethical Committee of the 
Government Kilpauk Medical College & Hospital Chennai. 
 
STUDY DESIGN: 
The study design is a cross sectional study. 
 
POPULATION: 
The study population included 50 patients who attended the Haemophilia 
OP at Government Royapettah Hospital and in-patients in the same hospital. 
 
INCLUSION CRITERIA: 
Patients diagnosed as Haemophilia and attending the Haemophilia OP. 
Newly diagnosed in- patients in Government Royapettah Hospital. 
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EXCLUSION CRITERIA: 
1. Patients with acute infections 
2. Patients with recent blood transfusion 
3. Patients with haemorrhoids and portal hypertension 
 
METHODOLOGY: 
All patients, diagnosed and registered in the Haemophilia clinic were 
taken as the study population. The sample size was set to be 50. A detailed 
history regarding the onset and progression of the disease, family history, 
maternal carrier status, treatment history and the presence of complications 
were taken. 
After obtaining consent blood was drawn for investigations. 
The following investigations were done: 
 aPTT 
 BT 
 CBC 
 HIV 
 HBsAg 
 Anti HCV 
 Hb levels 
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 Ferritin levels 
 Peripheral smear 
The results obtained were then analysed to identify iron deficiency and the 
clinic haematological profile in Haemophilia patients. 
Serum ferritin concentration is proportional to the amount of iron in the body. 
It was measured using immunoassay method. 
Step 1 – The binding of human serum ferritin to a solid phase antihuman 
ferritin and the simultaneous binding of the purified antihuman ferritin 
conjugated with ALP to the insoluble immune complex. 
Step 2 – Reaction of ALP with a substrate solution consisting of 
phenyphosphate disodium and 4-amino antipyrine. Following the addition of 
potassium ferricyanide a colour develops, the optical density (490-510nm) 
of which is directly proportional to the ferritin in the sample. 
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STATISTICAL ANALYSIS 
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STATISTICAL ANALYSIS 
The data obtained was analysed using the SSPS software.  
AGE DISTRIBUTION: 
 
 
 Age in years 
 
 
 
From the analysis, 40% of the patients were less than 20 yrs of age 
contributing to the highest percentage. 16% of the patients were between the age 
group of  41 to 50 yrs of age. 
The mean age of the study population was 25.28yrs. 
 Frequency Percent Valid Percent Cumulative Percent 
Valid <= 20 20 40.0 40.0 40.0 
21-30 12 24.0 24.0 64.0 
31-40 10 20.0 20.0 84.0 
41-50 8 16.0 16.0 100.0 
Total 50 100.0 100.0   
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SEX DISTRIBUTION: 
All the patients under the study were male. Female haemophiliacs were 
not identified in the study population. 
 
CARRIER STATUS DISTRIBUTION: 
 
 Mother's Carrier Status 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Not known 46 92.0 92.0 92.0 
Carrier 
positive 4 8.0 8.0 100.0 
Total 50 100.0 100.0   
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Of the study population of 50, only 8% knew the carrier status of their 
mother. The rest of the 92% were not aware of their maternal carrier status. 
 
FAMILY HISTORY ANALYSIS: 
 
 
 
  Frequency Percent Valid Percent Cumulative Percent 
Valid No 19 38.0 38.0 38.0 
Not known 10 20.0 20.0 58.0 
Yes 21 42.0 42.0 100.0 
Total 50 100.0 100.0  
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In the group of 50 haemophiliacs, 30% had no family history. 20% were 
not aware of their grandfather’s or uncle’s disease status. 42% had a positive 
family history either in their maternal grandfather or maternal uncle. 
 
AGE AT DIAGNOSIS: 
 
 
 N Minimum Maximum Mean Std. Deviation 
Age at Diag 50 1 24 6.58 5.845 
Valid N (listwise) 50         
 
The age at diagnosis was expressed in months and the mean age at 
diagnosis was found to be 6.58 months. 
The earliest was at 1 month of age and the latest was at 24 months of age. 
The age at diagnosis correlated best with the age of crawling indicating 
that diagnosis was made when the child was exposed to minor trauma and most 
of them had a history of purpuric patches on the skin.  
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HAEMOPHILIA TYPE ANALYSIS: 
 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid A 
40 80.0 80.0 80.0 
B 
6 12.0 12.0 92.0 
Inhibitor to factor 8 
pos 4 8.0 8.0 100.0 
Total 
50 100.0 100.0   
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Of the study population  
 80% were Haemophilia A 
 6% were Haemophilia B 
 4% had positive inhibitors to Factor VIII and were severe haemophiliacs 
 
 
SEVERITY OF HEMOPHILIA: 
 
 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Mild 3 6.0 6.0 6.0 
Mild B 3 6.0 6.0 12.0 
Moderate 5 10.0 10.0 22.0 
Severe 32 64.0 64.0 86.0 
Severe B 3 6.0 6.0 92.0 
Severe with 
inhibitor 4 8.0 8.0 100.0 
Total 50 100.0 100.0   
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The analysis showed the following results: 
 6% - Mild Haemophilia A 
 10% - Moderate Haemophilia A 
 64% - Severe Haemophilia A 
 8% - Severe Haemophilia A with positive inhibitors 
 6% - Mild Haemophilia B 
 6%- Severe Haemophilia B 
 
TYPE OF TREATMENT: 
 
Type of Treatment 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid On Demand 50 100.0 100.0 100.0 
 
100% of the population were on, on demand treatment with either factor or 
blood products. 
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TREATMENT WITH BLOOD AND BLOOD PRODUCTS: 
 
Blood and Bld Products 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Nil 
41 82.0 82.0 82.0 
Plasma 
5 10.0 10.0 92.0 
Blood 
4 8.0 8.0 100.0 
Total 
50 100.0 100.0   
 
 
 
 
 
 
Results of the analysis showed: 
 18% of the study population had received treatment with blood and blood 
products in their life time 
 82% had received only factor replacement. 
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DISTRIBUTION OF ARTHROPATHY: 
Arthropathy 
 
  Frequency Percent Valid Percent Cumulative Percent 
Valid Yes 8 16.0 16.0 16.0 
No 42 84.0 84.0 100.0 
Total 50 100.0 100.0   
 
 
 
As per the analysis, of the 50 patients studied, 16% had significant joint 
deformities. The rest of the 84% had normal range of movements. 
 
The arthropathy occurs due to iron deposition and fibrosis of the 
synovium. Repeated hemarthrosis can accelerate the arthropathy process thereby 
affecting the patients’ quality of life. 
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INFECTIOUS COMPLICATIONS: 
 
HIV: 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 1 2.0 2.0 2.0 
No 49 98.0 98.0 100.0 
Total 50 100.0 100.0   
 
 
 
 
HBsAg: 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 2 4.0 4.0 4.0 
No 48 96.0 96.0 100.0 
Total 50 100.0 100.0   
 
 
 
HCV: 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Yes 1 2.0 2.0 2.0 
No 49 98.0 98.0 100.0 
Total 50 100.0 100.0   
 
 
Of the study population, 2% were HIV infected, 4% were infected with 
Hepatitis B and 2% were HCV positive. These infections might be due to the 
usage of blood and blood products in the past. 
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ANANLYSIS OF aPTT: 
 
 aPTT (Sec) 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Normal 
26 52.0 52.0 52.0 
Abnormal 
24 48.0 48.0 100.0 
Total 50 100.0 100.0   
 
 
aPTT analysis showed an abnormal value (>40seconds) in about 48% of 
the study population. The rest of the 52% had normal aPTT values. 
The prolonged aPTT signifies a clotting factor defect especially in the 
intrinsic and the common pathway.  
The average aPTT is 54.20 seconds. 
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HEMOGLOBIN ANALYSIS: 
 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Normal 14 28.0 28.0 28.0 
Abnormal 36 72.0 72.0 100.0 
Total 50 100.0 100.0   
  
 
The result analysis showed that 72% had an abnormal Hb level of less 
than 13mgs/dl. Only 28% had a value greater than 13mgs/dl. 
 
The mean haemoglobin in the study population was 12.18 mgs/dl. 
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PERIPHERAL SMEAR ANALYSIS: 
 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Normal 42 84.0 84.0 84.0 
Microcytic 
hypochromic 
anemia 
8 16.0 16.0 100.0 
Total 50 100.0 100.0   
 
 
 
The results of peripheral smear analysis were as follows: 
 84% had a normal peripheral smear 
 16% had a peripheral smear with microcytic hypochromic anemia picture  
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ASSOCIATION BETWEEN SEVERITY OF HAEMOPHILIA AND 
PRESENCE OF ARTHROPATHY: 
 
Severity of Haemophilia * Arthropathy Crosstabulation 
 
    
Arthropathy 
Total Yes No 
Severity of 
Haemophilia 
Mild A Count 0 3 3 
% within Severity of 
Haemophilia .0% 100.0% 100.0% 
% within 
Arthropathy .0% 7.1% 6.0% 
Mild B Count 0 3 3 
% within Severity of 
Haemophilia .0% 100.0% 100.0% 
% within 
Arthropathy .0% 7.1% 6.0% 
Moderate A Count 0 5 5 
% within Severity of 
Haemophilia .0% 100.0% 100.0% 
% within 
Arthropathy .0% 11.9% 10.0% 
Severe A Count 6 26 32 
% within Severity of 
Haemophilia 18.8% 81.3% 100.0% 
% within 
Arthropathy 75.0% 61.9% 64.0% 
Severe B Count 0 3 3 
% within Severity of 
Haemophilia .0% 100.0% 100.0% 
% within 
Arthropathy .0% 7.1% 6.0% 
Severe A with 
inhibitor 
Count 2 2 4 
% within Severity of 
Haemophilia 50.0% 50.0% 100.0% 
% within 
Arthropathy 25.0% 4.8% 8.0% 
Total Count 8 42 50 
% within Severity of 
Haemophilia 16.0% 84.0% 100.0% 
% within 
Arthropathy 100.0% 100.0% 100.0% 
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The analysis were as follows  
 Among the patients with mild Haemophilia A and B none had 
arthropathy. 
 None of the patients with moderate haemophilia A have arthropathy. 
 Of the patients with severe Haemophilia A , 75% had arthropathy. 
 Among the Severe Haemophilia B, none had arthropathy. 
 Those who were positive for inhibitors against factor VIII were also 
severe haemophiliacs and of them 50% had arthropathy. 
 
 
Severity of Hemophlia
Severe w ith inhibito
Severe B
Severe
Moderate
Mild B
Mild
Co
u
n
t
30
20
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0
Arthropathy
Yes
No
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The arthropathy was majorly grouped in patients with severe haemophilia 
A, with or without the presence of inhibitors. This might probably be linked to 
the increased prevalence of joint bleeds in patients with severe deficiency of 
Factor VIII. 
FERRITIN IN THE STUDY POPULATION: 
 N Mean Std. Deviation Minimum Maximum 
            
Mild A 3 54.100 14.8987 37.7 66.8 
Mild B 3 51.800 18.2000 32.0 67.8 
Moderate A 5 48.200 11.4140 34.0 64.0 
Severe A 32 51.091 19.1329 21.0 89.0 
Severe B 3 58.167 12.2712 44.0 65.5 
Severe A with inhibitor 4 51.150 22.6530 22.0 72.6 
Total 50 51.454 17.5141 21.0 89.0 
 
 
 ANOVA 
 
Ferritin (Ng/Ml)  
  
Sum of 
Squares df Mean Square F Sig. 
Between Groups 214.080 5 42.816 .127 .985 
Within Groups 14816.284 44 336.734     
Total 15030.364 49       
 
Results showed, 
 The mean Ferritin in Mild haemophilia A was 54ng/ml. 
 The mean ferritin in Mild Haemophilia B was 51.8ng/ml. 
 The mean ferritin in Moderate Haemophilia A was 48.2ng/ml. 
 The mean ferritin in Severe Haemophilia A was 51.09ng/ml 
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 The mean ferritin in Severe Haemophilia A with inhibitors was 
51.15ng/ml. 
 The mean ferritin in severe Haemophilia B was 58.16ng/ml. 
ANALYSIS BETWEEN SEVERITY OF HAEMOPHILIAAND 
FERRITIN LEVELS: 
   
Ferritin (Ng/Ml) 
Total < 50 50-100 
Severity of 
Haemophilia 
Mild A Count 1 2 3 
% within Severity of 
Haemophilia 33.3% 66.7% 100.0% 
% within Ferritin 
(Ng/Ml) 3.6% 9.1% 6.0% 
Mild B Count 1 2 3 
% within Severity of 
Haemophilia 33.3% 66.7% 100.0% 
% within Ferritin 
(Ng/Ml) 3.6% 9.1% 6.0% 
Moderate A Count 3 2 5 
% within Severity of 
Haemophilia 60.0% 40.0% 100.0% 
% within Ferritin 
(Ng/Ml) 10.7% 9.1% 10.0% 
Severe A Count 20 12 32 
% within Severity of 
Haemophilia 62.5% 37.5% 100.0% 
% within Ferritin 
(Ng/Ml) 71.4% 54.5% 64.0% 
Severe B Count 1 2 3 
% within Severity of 
Haemophilia 33.3% 66.7% 100.0% 
% within Ferritin 
(Ng/Ml) 3.6% 9.1% 6.0% 
Severe A with 
inhibitor 
Count 2 2 4 
% within Severity of 
Haemophilia 50.0% 50.0% 100.0% 
% within Ferritin 
(Ng/Ml) 7.1% 9.1% 8.0% 
Total Count 28 22 50 
% within Severity of 
Haemophilia 56.0% 44.0% 100.0% 
% within Ferritin 
(Ng/Ml) 100.0% 100.0% 100.0% 
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Analysis showed Ferritin levels between 50to100ng/ml in, 
 66.7% of mild haemophilia A patients 
 40% of Moderate Haemophilia A patients 
 37.5% of Severe Haemophilia A patients 
 66.7% of Mild Haemophilia B 
 66.7% of severe Haemophilia B 
 50% of Severe haemophilia with inhibitors 
A ferritin level of less than 50ng/ml was seen in 
 33.3% of Mild Haemophilia A patients 
 60% of Moderate Haemophilia A patients 
 62.5% of Severe Haemophilia A patients 
 33.3% of Mild Haemophilia B 
 33.3% of Severe Haemophilia B 
 50% of Severe Haemophilia with inhibitors 
The results showed that though the ferritin was within normal value, they 
were in the lower range of normal. Patients with severe Haemophilia had a 
much lower ferritin level than those with mild or moderate disease. The results 
were inconclusive in the Inhibitor group with 50% of the population having low 
normal ferritin values. 
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ASSOCIATION BETWEEN SEVERITY OF HAEMOPHILIA AND 
PRESENCE OF MICROCYTIC HYPOCHROMIC PICTURE IN THE 
PERIPHERAL SMEAR: 
Severity of Haemophilia * Peripheral Smear Crosstabulation 
 
    
Peripheral Smear 
Total Normal 
Microcytic 
hypochromic 
anemia 
Severity of 
Haemophilia 
Mild A Count 3 0 3 
% within Severity 
of Haemophilia 100.0% .0% 100.0% 
% within Peripheral 
Smear 7.1% .0% 6.0% 
Mild B Count 2 1 3 
% within Severity 
of Haemophilia 66.7% 33.3% 100.0% 
% within Peripheral 
Smear 4.8% 12.5% 6.0% 
Moderate A Count 4 1 5 
% within Severity 
of Haemophilia 80.0% 20.0% 100.0% 
% within Peripheral 
Smear 9.5% 12.5% 10.0% 
Severe A Count 27 5 32 
% within Severity 
of Haemophilia 84.4% 15.6% 100.0% 
% within Peripheral 
Smear 64.3% 62.5% 64.0% 
Severe B Count 3 0 3 
% within Severity 
of Haemophilia 100.0% .0% 100.0% 
% within Peripheral 
Smear 7.1% .0% 6.0% 
Severe A with 
inhibitor 
Count 3 1 4 
% within Severity 
of Haemophilia 75.0% 25.0% 100.0% 
% within Peripheral 
Smear 7.1% 12.5% 8.0% 
Total Count 42 8 50 
% within Severity 
of Haemophilia 84.0% 16.0% 100.0% 
% within Peripheral 
Smear 100.0% 100.0% 100.0% 
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The analysis showed, 
 Of the patients with mild haemophilia A, all had a normal peripheral 
smear. 
 There were 3 pts with mild haemophilia B and 1 was positive for a 
microcytic hypochromic peripheral smear, making it a 33.3% prevalence 
in the mild Haemophilia B group. 
 20% of the moderate Haemophilia A had an abnormal peripheral smear 
picture. 
 The Severe Haemophilia A without inhibitors included 32 patients. Of 
them 5 were positive for an abnormal peripheral smear. This is about 
15.6% of the severe haemophiliacs. 
 Of the severe Haemophilia A with inhibitor 25% had an abnormal 
peripheral smear. 
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ANALYSIS BETWEEN TARGET JOINT AND SEVERITY OF 
HEMOPHILIA 
   
Severity of Haemophilia 
Total Mild Mild B 
Modera
te Severe 
Severe 
B 
Severe 
with 
inhibitor 
Target 
Joint 
Right 
knee 
Count 1 2 0 8 0 0 11 
% within 
Target 
Joint 
9.1% 18.2% .0% 72.7% .0% .0% 100.0% 
% within 
Severity 
of 
Haemop
hilia 
33.3% 66.7% .0% 25.0% .0% .0% 22.0% 
Left 
knee 
Count 0 1 2 6 1 2 12 
% within 
Target 
Joint 
.0% 8.3% 16.7% 50.0% 8.3% 16.7% 100.0% 
% within 
Severity 
of 
Haemop
hilia 
.0% 33.3% 40.0% 18.8% 33.3% 50.0% 24.0% 
Right 
ankle 
Count 2 0 2 6 0 1 11 
% within 
Target 
Joint 
18.2% .0% 18.2% 54.5% .0% 9.1% 100.0% 
% within 
Severity 
of 
Haemop
hilia 
66.7% .0% 40.0% 18.8% .0% 25.0% 22.0% 
left ankle Count 0 0 0 7 1 1 9 
% within 
Target 
Joint 
.0% .0% .0% 77.8% 11.1% 11.1% 100.0% 
% within 
Severity 
of 
Haemop
hilia 
.0% .0% .0% 21.9% 33.3% 25.0% 18.0% 
Left hip Count 0 0 1 3 0 0 4 
% within 
Target 
Joint 
.0% .0% 25.0% 75.0% .0% .0% 100.0% 
% within 
Severity 
of 
Haemop
hilia 
.0% .0% 20.0% 9.4% .0% .0% 8.0% 
Left 
elbow 
Count 0 0 0 1 1 0 2 
% within 
Target 
Joint 
.0% .0% .0% 50.0% 50.0% .0% 100.0% 
% within 
Severity 
of 
Haemop
hilia 
.0% .0% .0% 3.1% 33.3% .0% 4.0% 
Right 
elbow 
Count 0 0 0 1 0 0 1 
% within 
Target 
Joint 
.0% .0% .0% 100.0% .0% .0% 100.0% 
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Analysis showed that the weight bearing joints – knees and ankles were 
most commonly affected.  Right knee bleed contributed to 22% of the total 
bleeds in Haemophilia patients. Left knee contributed to 24% of the total joint 
bleeds in Haemophiliapatients.  
Right ankle bleeds contributed to 22% and left ankle bleeds to 18% of the 
bleeding manifestations. This shows that weight bearing joints are more 
commonlt affected. The other joints had a minor percentage contribution. 
 
% within 
Severity 
of 
Haemop
hilia 
.0% .0% .0% 3.1% .0% .0% 2.0% 
Total Count 3 3 5 32 3 4 50 
% within 
Target 
Joint 
6.0% 6.0% 10.0% 64.0% 6.0% 8.0% 100.0% 
% within 
Severity 
of 
Haemop
hilia 
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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DISCUSSION 
PREVELANCE AND GLOBAL STAND 
The analysis showed that the age group that formed the major group of 
patients was less than 20 yrs of age. This is probably due to the better 
diagnosistic facilities available and better awareness among the general public 
and the carrier parents. Patients betweet 41 and 50 yrs of age contributed a less 
proportion of the total study population.  
Indian data from 2011 showed that there were 14,718 patients with 
nleeding disorder and of that 11,586 patients were HaemophiliaA6. India reports 
the second largest number in patients with bleeding disorders and the third 
largest in those with HaemophiliaA4. 
ESTIMATED NUMBER OF PATIENTS 
The prevalence of Haemophilia A in India is around 0.9 per 1,00,000 
people.  This low number of prevalence might reflect the underdiagnosis, under 
reporting and early mortality of cases. When compared with the developed 
world the rate of case detection in India is 5 times lesser than that in the 
developed world. 
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Using the population data for 2011 from the Census of India15 and a 
prevalence of haemophilia A of 4 per 1,00,000, the estimated number of 
haemophilia patients in India would be around 48,4076.  
Haemophilia B has a lower prevalence rate of 0.1 per 1,00,000 
population. This shows the need for better surveilance and case reporting in 
India. The estimated patients with HaemophiliaB would cross 20,000 in number. 
With this study incidence and prevalence of the study could not be 
estimated as its a cross sectional descriptive study. 
 
CASE DETECTION 
India has reported the second maximum newly diagnosed cases in the 
world, in the last one year. However, studies for predicting the future trends in 
hemophila in India is absent. With better laboratory services and better 
awareness among both the patients and the doctors, the number of newly 
diagnosed cases might increase. 
Observed estimated and real prevalence of Hemophlillia patients in the 
various states of India and the union territories have been represented in the 
following pictorial representation.  
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ORTHOPEDIC COMPLICATIONS 
In this study arthropathy was seen in 16% of the study opulation. 
However, in a study by Kar et al, prevalence of the disability has been 
estimated. According to this study, of 148 patients with severe Haemophilia A 
only 9 were free of disability7.  The orthopedic complications were seen more in 
those who belonged to the lower socio economic group. Kar et al found the 
increaseed incidence of fractures in patients with severe Haemophilia on follow 
up. 
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In this study follow up was not done and the socio economic status was 
not analysed. In this study only 16% had arthropathy but all the 16% were 
severe Haemophilia patients. 
TRANSFUSION RELATED INFECTIONS 
In remote areas where access to factor replacement is difficult, usage of 
blood and blood producs can result in the transmission of infections. No specific 
data is available regarding the usage of blood products by haemophilic patients 
at the national level. In this study involving 50 patients from our hospital, 10% 
had received plasma transfusion and 8% had received whole blood transfusion. 
The Annual Global Report 2011 showed that 1.12% of Haemophilia 
patients were HIV positive. There is one large study that shows the prevalence 
of HIV, HBsAg and HCV in hemophilics. According to that 323 severe and 77 
moderate Haemophilia  patients had transfusion related infections4. 
In this study, 2% of the 50 were positive for HIV, 2% were positive for 
HCV and 4% were positive for HBsAg. All those whohad infection were severe 
Hemophilics. And of those who were infected 50% had a positive history of 
receiving blood or blood products in the past. 
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The method of testing used for HCV also had a significance in the 
outcome. When RT-PCR was used the prevalence was 7.1% and when ELISA 
was used prevalence dropped to 6.2%6. 
INHIBITORS 
Development of inhibitors to factor VIII concentrates is the most dreaded 
of complications. Factor VIII concentrate is neutralized by the inhibitors. These 
inhibitors are alloantibodies with high affinity. They belng to the IgG subclass. 
In this study, 8% were positive for inhibitors and all were severe 
Haemophiliawith Factor VIII levels less than 1%.  
Studies in India showed that the prevalence of inhibitors were found to be 
8.3 to 12%4.  
The treatment for inhibitors is Immune tolerance induction. In view of the 
expense involved in ITI treatment, initiating treatment plans in India is still 
under question.   
TYPE OF TREATMENT 
There are two types of treatment in Haemophilia– On demand and 
Prophylactic treatment. Though prophylactic treatment has a decreased 
incidence of joint complications, the cost of treatment per patient is high. 
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Though India is the second largest in the number of Haemophilia patients 
our per capita usage of factor products was only 0.032 when compared to USA 
which had a per capita usage of 5.17. 
In view of the cost and the inacessebility to Haemophilia treatment 
centres, Indian patients are still under on demand treatment. Prophylactic 
treatment is still under study in our population. 
JOINT INVOLVEMENT 
The weight bearing joints are more commonly affected in Hemophilia. 
This has been shown in the study by the greater percentage contribution of knee 
and ankle bleeds. The frequent joint bleeds cause damage and result in 
arthropathy that can severly affect the quality of patient’s life. Most people tend 
to discontinue their job in view of their arthropathy thereby increasing the 
economic burden of the family. 
FERRITIN AND PERIPHERAL SMEAR 
In this study it was found that ferritin levels were in the low normal range 
in people with severe Hemophilia. Arthropathy was more in the same group of 
population. The low ferritin can be attributed to the frequent bleeding and 
hemosiderin deposition in the synovium contributing to the arthropathy. 
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CONCLUSION 
Haemophilia is an inherited bleeding disorder with X linked inheritance. 
Majority of the Haemophilia are factor VIII deficient and have factor levels less 
than 1%. The genetic make up and the profile of the patients vary in the ethnic 
groups of India. Prevention of Hemophilic birth is limited in our country due to 
the absence of prenatal diagnostic facilities. Treatment facilities in our country 
need to be improved to make the fcators available for the patients belonging to 
the lower socio economic group.  
The results from the analysis is as follows: 
 Majority of the sample population were less than 20 yrs of age. 
 Female Hemophiliacs (due to disporportionate lyonisation of the X 
chromosome), were not identified in the study group. 
 Only 8% of the patients’ were aware of their mother’s carrier status. 
 Haemophilia A is more common contributing to 80% of the Haemophilia 
population. 12% were Hemophiliac B. 
 Most of the Hemophiliacs had factor levels less than 1% and belonged to 
the group of severe hemophiliacs. 
 8% of the study population were inhibitor positive. 
 A majority of the popultion had a family history of Hemophilia. 20% had 
no family history. 
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 The mean age of diagnosis was 6.58 months, the average month when an 
infant begins to crawl. 
 The weight bearing joints were more commonly involved in recurrent 
bleeding episodes with both the knees having the highest percentage. 
 With the advent of plasma derived factors the use of blood related factors 
have decreased. Despite this 18% had a history of Blood or plasma 
transfusions in the past. 
 Since prophylactic treatment is still under study, all the patients were 
under on demand treatment. 
 Arthropathy, a major complication due to recurrent bleed was seen in 
16% of the study population and of the 16% majority were severe 
hemophiliacs. 
 With the use of blood, blood products and plasma derived factors, the 
prevalence of  transfusion related infections can be high. In our group 4% 
were positive for HBsAg, 2% for HIV and 2% for HCV. 
 Majority of the patients had a low Hb of less than 13mg/dl. 
 16% of the patients had a microcytic hypochromic picture on their 
peripheral smear. The distribution of the abnormal smear was such that, 
majority were in the Severe Hemophiliacs and the Hemophiliacs with 
inhibitors. 
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 The mean ferritin was found to be 51.45ng/dl which is in the low normal 
range. The mean ferritin was found to be low in moderate and severe 
hemophiliacs. 
 All patients had a low normal ferritin value with the lowest values in the 
moderate and severe hemophiliac groups. 
 
LIMITATIONS OF THE STUDY 
 The sample size was small (50 patients). A larger size would have given 
better comparable results. 
 Short duration of study. 
 A scoring system for the arthropathy was not used. Severity of the 
arthropathy was not graded. 
 Serum Iron was not evaluated. 
 Analysis of other bleeding manifestations were not done. 
 Availability of very few literature  for incidence and prevalence 
calculation. 
Further studies involving a larger population is needed for better analysis.  
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ANNEXURES 
                                            PROFORMA 
NAME:     MOTHER’S NAME: 
AGE:      CARRIER STATUS: 
SEX:       PHONE NO: 
OCCUPATION: 
ADDRESS: 
EDUCATIONAL STATUS OF THE PATIENT: 
I.BLEEDING 
FACTOR DEFICIENT (IF ALREADY KNOWN) : 
AGE AT 1ST DIAGNOSIS: 
REASON FOR CONSULTATION AT 1ST DIAGNOSIS: 
Minor trauma/major trauma/skin bleeds/mucosal 
bleeds/hematuria/hematemesis/hematochezia/surgery/ dental procedures 
FREQUENCY OF BLEED PER YEAR : (Average) 
MOST COMMON BLEED SITE: 
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Joint: 
Muscle: 
Mucosal: 
 
 
PREVIOUS HISTORY OF : 
1. Joint bleed  :   Most common: 
2. Muscle bleed:  Most common: 
3. Nose bleed: 
4. Skin bleed: 
5. Hematuria; 
6. Eye bleeds: 
7. Intracranial bleed: 
 
II. TREATMENT HISTORY: 
HISTORY OF BLOOD PRODUCTS TANSFUSION: 
 
BLOOD PRODUCTS REQUIRED : FFP/Cryo-ppt/Whole blood/Packed cell/Others 
 
HISTORY OF USAGE OF NON BLOOD PRODUCTS: 
Desmopressin/ EACA/ Transexamic acid/ other antifibrinolytics/FEIBA/others 
 
TYPE OF TREATMENT : On demand / Prophylactic 
 
III.COMPLICATIONS :  
 
1.Musculoskeletal complications :  
 Chronic arthropathy 
 Contractures 
 Fractures 
2.Clnical suspicion of presence of inhibitors: 
3.Transfusion related complications :  
Hep B/Hep C/HIV/Others 
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IV.DETAILS OF PREVIOUS HOPSITALIZATION 
 No. Of times received Factor: 
 Previous hopsitalization: 
 No of times hospitalized so far: 
 Details of previous Hopsitalization: 
 
INVESTIGATIONS 
 
FACTOR VIII 
FACTOR IX 
SEVERITY OF HEMOPHILIA: 
BT: 
CT: 
PT: 
aPTT: 
 
INHIBITORS: 
 
FERRITIN: 
 
 
 
 
 
 
 
FAMILY HISTORY OF HEMOPHILIA :  (Pedigree) 
 
 
 
HISTORY OF INHIBITOR POSITIVITY:  
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